During the last session, Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)’s traded shares were 1.95 million, with the beta value of the company hitting 1.28. At the end of the trading day, the stock’s price was $9.17, reflecting an intraday loss of -2.65% or -$0.25. The 52-week high for the ICPT share is $21.86, that puts it down -138.39 from that peak though still a striking -0.22% loss since the share price plummeted to a 52-week low of $9.19. The company’s market capitalization is $382.30M, and the average intraday trading volume over the past 10 days was 2.68 million shares, and the average trade volume was 1.09 million shares over the past three months.

Intercept Pharmaceuticals Inc. (ICPT) received a consensus recommendation of a Hold from analysts. That translates to a mean rating of 2.80. ICPT has a Sell rating from 2 analyst(s) out of 16 analysts who have looked at this stock. 10 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 2 recommend a Buy rating for it. 1 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.55.

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) trade information

Intercept Pharmaceuticals Inc. (ICPT) registered a -2.65% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.65% in intraday trading to $9.17 this Wednesday, 05/24/23, hitting a weekly high. The stock’s 5-day price performance is -43.43%, and it has moved by -51.64% in 30 days. Based on these gigs, the overall price performance for the year is -47.48%. The short interest in Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) is 3.69 million shares and it means that shorts have 4.53 day(s) to cover.

The consensus price target of analysts on Wall Street is $20.17, which implies an increase of 54.54% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $8.00 and $54.00 respectively. As a result, ICPT is trading at a discount of -488.88% off the target high and 12.76% off the low.

Intercept Pharmaceuticals Inc. (ICPT) estimates and forecasts

Statistics show that Intercept Pharmaceuticals Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Intercept Pharmaceuticals Inc. (ICPT) shares have gone down -39.27% during the last six months, with a year-to-date growth rate more than the industry average at 28.86% against 11.40. Yet analysts are ramping up their growth forecast for the fiscal year 2023. Revenue is predicted to shrink -120.00% this quarter and then drop -108.20% in the quarter after that. In the rating firms’ projections, revenue will increase 14.90% compared to the previous financial year.

Revenue for the current quarter is expected to be $78.74 million as predicted by 15 analyst(s). Meanwhile, a consensus of 15 analyst(s) estimates revenue growth to $86.05 million by the end of Sep 2023. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $71.76 million and $77.59 million respectively. In this case, analysts expect current quarter sales to grow by 9.70% and then jump by 10.90% in the coming quarter.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 18.50%. While earnings are projected to return -20.90% in 2023, the next five years will return -8.89% per annum.

ICPT Dividends

Intercept Pharmaceuticals Inc. is due to release its next quarterly earnings between August 01 and August 07. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)’s Major holders

Intercept Pharmaceuticals Inc. insiders own 3.20% of total outstanding shares while institutional holders control 79.59%, with the float percentage being 82.22%. Vanguard Group, Inc. (The) is the largest shareholder of the company, while 228 institutions own stock in it. As of Mar 30, 2023, the company held over 3.94 million shares (or 9.44% of all shares), a total value of $36.09 million in shares.

The next largest institutional holding, with 3.06 million shares, is of Blackrock Inc.’s that is approximately 7.34% of outstanding shares. At the market price on Mar 30, 2023, these shares were valued at $28.05 million.

Also, the Mutual Funds coming in first place with the largest holdings of Intercept Pharmaceuticals Inc. (ICPT) shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. Data provided on Feb 27, 2023 indicates that SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF owns about 2.26 million shares. This amounts to just over 5.41 percent of the company’s overall shares, with a $20.69 million market value. The same data shows that the other fund manager holds slightly less at 1.12 million, or about 2.70% of the stock, which is worth about $10.3 million.